AU · rank #2 · 2026-09-08
NUTX
NASDAQ · $1.31B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 3.088 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$4.84 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 5 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.186 |
| Analyst upside Consensus target $276.00 | +42.8% |
| Momentum acceleration 3-month minus 12-month momentum. | +11.71% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.67 |
| Gross margin TTM | +54.5% |
| 52w high | $204.00 |
| Market cap (USD) | $1.31B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Nutex Health Inc operates a network of physician-led micro-hospitals and outpatient departments alongside a Population Health Management division running risk-bearing provider networks.
Rationale
Strong analyst upside of 42.8% and positive EPS revisions are validated by robust operational momentum, highlighted by 82.4% year-over-year revenue growth in FY2025 and a massive 89.3% earnings surprise.
Material risks
- 1Severe exposure to out-of-network billing and the No Surprises Act's independent dispute resolution process makes revenue highly sensitive to adverse regulatory adjustments or strategic payer pushback.
- 2Historical restatements of 2025 quarterly financial results reflect internal accounting control deficiencies, posing ongoing risks of reporting delays or further revisions.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.